Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis M Lehrke, A Becker, M Greif, R Stark, RP Laubender, F von Ziegler, ... European journal of endocrinology 161 (2), 339-344, 2009 | 470 | 2009 |
Effect of ultrasound screening on the rate of first operative procedures for developmental hip dysplasia in Germany R von Kries, N Ihme, D Oberle, A Lorani, R Stark, L Altenhofen, ... The Lancet 362 (9399), 1883-1887, 2003 | 211 | 2003 |
Resistin is an inflammatory marker of inflammatory bowel disease in humans A Konrad, M Lehrke, V Schachinger, F Seibold, R Stark, T Ochsenkühn, ... European journal of gastroenterology & hepatology 19 (12), 1070-1074, 2007 | 173 | 2007 |
Costs of inflammatory bowel disease in Germany R Stark, HH König, R Leidl Pharmacoeconomics 24, 797-814, 2006 | 162 | 2006 |
Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes T Xu, S Brandmaier, AC Messias, C Herder, HHM Draisma, A Demirkan, ... Diabetes care 38 (10), 1858-1867, 2015 | 157 | 2015 |
A walnut-enriched diet affects gut microbiome in healthy caucasian subjects: a randomized, controlled trial C Bamberger, A Rossmeier, K Lechner, L Wu, E Waldmann, S Fischer, ... Nutrients 10 (2), 244, 2018 | 130 | 2018 |
Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany RG Stark, P Reitmeir, R Leidl, HH König Inflammatory bowel diseases 16 (1), 42-51, 2010 | 122 | 2010 |
Walnut-enriched diet reduces fasting non-HDL-cholesterol and apolipoprotein B in healthy Caucasian subjects: a randomized controlled cross-over clinical trial L Wu, K Piotrowski, T Rau, E Waldmann, UC Broedl, H Demmelmair, ... Metabolism 63 (3), 382-391, 2014 | 114 | 2014 |
Health care use and costs of adverse drug events emerging from outpatient treatment in Germany: a modelling approach RG Stark, J John, R Leidl BMC health services research 11, 1-9, 2011 | 100 | 2011 |
Cost burden of type 2 diabetes in Germany: results from the population-based KORA studies S Ulrich, R Holle, M Wacker, R Stark, A Icks, B Thorand, A Peters, M Laxy BMJ open 6 (11), e012527, 2016 | 92 | 2016 |
Low adiponectin levels are an independent predictor of mixed and non-calcified coronary atherosclerotic plaques UC Broedl, C Lebherz, M Lehrke, R Stark, M Greif, A Becker, F von Ziegler, ... PLoS One 4 (3), e4733, 2009 | 92 | 2009 |
Systemic cardiovascular complications in patients with long-standing diabetes mellitus: comprehensive assessment with whole-body magnetic resonance imaging/magnetic resonance … S Weckbach, HM Findeisen, SO Schoenberg, H Kramer, R Stark, ... Investigative radiology 44 (4), 242-250, 2009 | 76 | 2009 |
A walnut-enriched diet reduces lipids in healthy Caucasian subjects, independent of recommended macronutrient replacement and time point of consumption: a prospective … C Bamberger, A Rossmeier, K Lechner, L Wu, E Waldmann, RG Stark, ... Nutrients 9 (10), 1097, 2017 | 67 | 2017 |
Datenbankgestützte online-erfassung von arzneimitteln im rahmen gesundheitswissenschaftlicher studien-erfahrungen mit der IDOM-Software N Mühlberger, C Behrend, R Stark, R Holle Inform Biom Epidemiol Med Biol 34, 601-611, 2003 | 64 | 2003 |
The economic burden of obesity in Germany: results from the population-based KORA studies N Yates, CM Teuner, M Hunger, R Holle, R Stark, M Laxy, H Hauner, ... Obesity facts 9 (6), 397-409, 2017 | 55 | 2017 |
High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome IN Bähr, P Tretter, J Krüger, RG Stark, J Schimkus, T Unger, K Kappert, ... Hypertension 58 (4), 725-732, 2011 | 46 | 2011 |
Medical care of type 2 diabetes in German Disease Management Programmes: a population‐based evaluation RG Stark, MV Schunk, C Meisinger, W Rathmann, R Leidl, R Holle, ... Diabetes/metabolism research and reviews 27 (4), 383-391, 2011 | 46 | 2011 |
CXCL16 is a surrogate marker of inflammatory bowel disease M Lehrke, A Konrad, M Lehrke, A Konrad, V Schachinger, C Tillack, ... Scandinavian journal of gastroenterology 43 (3), 283-288, 2008 | 34 | 2008 |
Apolipoprotein A-IV is an independent predictor of disease activity in patients with inflammatory bowel disease UC Broedl, V Schachinger, A Lingenhel, M Lehrke, R Stark, F Seibold, ... Inflammatory bowel diseases 13 (4), 391-397, 2007 | 30 | 2007 |
The effectiveness of German disease management programs (DMPs) in patients with type 2 diabetes mellitus and coronary heart disease: results from an observational longitudinal … M Laxy, R Stark, C Meisinger, I Kirchberger, M Heier, W von Scheidt, ... Diabetology & metabolic syndrome 7, 1-11, 2015 | 29 | 2015 |